Elilyly每月推出一个新的四剂量Zepbound KwikPen(Zepbound KwikPen), 仅供现金付费患者使用, 价格为299-449美元/月, Eli Lilly launches a new four-dose Zepbound KwikPen for monthly use, available Feb. 23, 2026, priced $299–$449/month, for cash-paying patients only.

Eli Lilly为其重量损失药物Zepbound推出了一种新的四剂量KwikPen四剂量的Zepbound药物,该药物于1月下旬得到林业发展局的核准,使病人能够从一个装置上获得整整一个月的每周剂量。 Eli Lilly has launched a new four-dose KwikPen for its weight-loss drug Zepbound, approved by the FDA in late January, allowing patients to receive a full month of weekly doses from a single device. 从2026年2月23日起,通过LillyDirect,自付费病人的笔价为每月299至449美元,不适合视力障碍患者。 Available starting February 23, 2026, through LillyDirect, the pen is priced at $299 to $449 per month for self-paying patients and is not suitable for those with visual impairments. 这个装置已经用于Lilly的糖尿病药物Mounjaro,现在不能分享,目前只有付现金的病人可以使用;被保险的病人必须使用单剂量笔。 The device, already used for Lilly’s diabetes drug Mounjaro, is not shareable and is currently only available to cash-paying patients; insured patients must use single-dose pens. 泽普邦 (Zepbound) 超过了Wegovy成为2025年美国销量最高的减肥药,已被批准用于肥胖或超重的成年人,并与饮食和运动一起使用. Zepbound, which surpassed Wegovy as the top-selling weight-loss drug in the U.S. in 2025, is approved for adults with obesity or overweight with weight-related conditions, used alongside diet and exercise.